Dynavax Technologies Corporation (DVAX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
DVAX Revenue Growth
Revenue Breakdown (FY 2024)
DVAX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
DVAX Revenue Analysis (2013–2024)
As of May 8, 2026, Dynavax Technologies Corporation (DVAX) generated trailing twelve-month (TTM) revenue of $330.5 million, reflecting strong growth of +17.7% year-over-year. The most recent quarter (Q3 2025) recorded $94.9 million in revenue, down 0.6% sequentially.
Looking at the longer-term picture, DVAX's 5-year compound annual growth rate (CAGR) stands at +51.1%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $722.7 million in 2022.
Revenue diversification analysis shows DVAX's business is primarily driven by H E P L I S A V B (97%), and Other Revenue (3%). With over half of revenue concentrated in H E P L I S A V B, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NVAX (-52.5% YoY), SIGA (-22.1% YoY), and VXRT (+726.7% YoY), DVAX has underperformed the peer group in terms of revenue growth. Compare DVAX vs NVAX →
DVAX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DVAXCurrent | $331M | +17.7% | +51.1% | -1.5% | |
 NVAX | $1.1B | -52.5% | +118.8% | 50.1% | |
 SIGA | $95M | -22.1% | -5.4% | 25.1% | |
 VXRT | $237M | +726.7% | +125.8% | 7.6% | |
 IBRX | $15M | +1026.0% | +221.4% | -2334.2% |
DVAX Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $277.2M | +19.4% | $227.8M | 82.2% | $-4,122,000 | -1.5% |
| 2023 | $232.3M | -67.9% | $182.1M | 78.4% | $-37,028,000 | -15.9% |
| 2022 | $722.7M | +64.5% | $460.5M | 63.7% | $283.5M | 39.2% |
| 2021 | $439.4M | +844.0% | $265.9M | 60.5% | $134.5M | 30.6% |
| 2020 | $46.6M | +32.2% | $32.6M | 70.1% | $-75,222,000 | -161.6% |
| 2019 | $35.2M | +329.6% | $15.8M | 44.9% | $-134,843,000 | -382.9% |
| 2018 | $8.2M | +2407.0% | $-13,598,000 | -165.9% | $-153,319,000 | -1870.2% |
| 2017 | $327K | -97.0% | $-867,000 | -265.1% | $-96,005,000 | -29359.3% |
| 2016 | $11.0M | +172.7% | $11.0M | 100.0% | $-110,707,000 | -1002.5% |
| 2015 | $4.0M | -63.3% | $4.0M | 100.0% | $-105,073,000 | -2594.4% |
See DVAX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DVAX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DVAX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDVAX — Frequently Asked Questions
Quick answers to the most common questions about buying DVAX stock.
Is DVAX's revenue growth accelerating or slowing?
DVAX revenue is accelerating at +17.7% year-over-year, exceeding the 5-year CAGR of +51.1%. TTM revenue reached $331M. Growth momentum has increased versus prior periods.
What is DVAX's long-term revenue growth rate?
Dynavax Technologies Corporation's 5-year revenue CAGR of +51.1% reflects the sustained expansion pattern. Current YoY growth of +17.7% is above this long-term average.
How is DVAX's revenue distributed by segment?
DVAX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.